At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 240 enrolled
Drug / intervention
Fluzone Quadrivalent vaccine +2 morebiological
Likely dose
Fluzone Quadrivalent vaccine 0.25 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines, 2017-2018 Formulations
In Brief
A Phase 4 clinical trial evaluating Fluzone Quadrivalent vaccine and Fluzone High-Dose vaccine for Influenza and Flu. Completed, enrolled 240 participants across 3 sites.
Detailed Summary
The aim of the study was to describe the safety and immunogenicity of the 2017-2018 formulation of Fluzone Quadrivalent vaccine in children 6 months to \< 9 years of age, and in adults 18 to \< 65 years of age, and to describe the safety and immunogenicity of the 2017-2018 formulation of Fluzone High-Dose vaccine in adults ≥ 65 years of age.
Study Details
Timeline
Phase 4CompletedFinished
201820192020202120222023202420252026
Enrollment StartSep 2017
First PostedOct 2017
Primary CompletionNov 2017
TodayJul 2026
First PostedOct 13, 2017
Enrollment StartSep 11, 2017
Primary CompletionNov 22, 2017
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 8.7 years ago
Interventions
Fluzone Quadrivalent vaccinebiological
0.25 mL, Intramuscular
Fluzone Quadrivalent vaccinebiological
0.5 mL, Intramuscular
Fluzone High-Dose vaccinebiological
0.5 mL, Intramuscular